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Highlights 26 
1. The IPP-bypass pathway was optimized to substantially improve isoprenol titer. 27 
2. PMD mutant was introduced for MVAP conversion with high efficiency.  28 
3. Isoprenol titer reached 3.7 g/L in batch cultures at 44% of the theoretical yield. 29 
4. The highest isoprenol titer (10.8 g/L) was achieved in fed-batch fermentations.  30 
5. Use of a solvent overlay improved titer by removing the toxic final product.   31 
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Abstract 32 
Isoprenol (3-methyl-3-buten-1-ol) is a drop-in biofuel and a precursor for commodity 33 
chemicals. Biological production of isoprenol via the mevalonate pathway has been 34 
developed and optimized extensively in Escherichia coli, but high ATP requirements and 35 
isopentenyl diphosphate (IPP) toxicity have made it difficult to achieve high titer, yield, 36 
and large-scale production. To overcome these limitations, an IPP-bypass pathway was 37 
previously developed using the promiscuous activity of diphosphomevalonate 38 
decarboxylase, and enabled the production of isoprenol at a comparable yield and titer to 39 
the original pathway. In this study, we optimized this pathway, substantially improving 40 
isoprenol production. A titer of 3.7 g/L (0.14 g isoprenol per g glucose) was achieved in 41 
batch conditions using minimal medium by pathway optimization, and a further 42 
optimization of the fed-batch fermentation process enabled an isoprenol titer of 10.8 g/L 43 
(yield of 0.105 g/g and maximum productivity of 0.157 g L-1 h-1), which is the highest 44 
reported titer for this compound. The substantial increase in isoprenol titer via the IPP-45 
bypass pathway in this study will facilitate progress toward commercialization.  46 
 47 
 48 
Keywords: Isoprenol; IPP-bypass; mevalonate pathway; biofuel; fermentation; 49 
bioconversion   50 
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1. Introduction 51 
Increasing concerns about the cost and environmental impact of petroleum-derived fuels 52 
(Baral et al., 2019) has motivated the development of microbial hosts for the production 53 
of fuels from renewable carbon sources (Cheon et al., 2016; Liao et al., 2016; Meadows 54 
et al., 2018; Rabinovitch-Deere et al., 2013). In particular, 3-methyl-3-buten-1-ol 55 
(isoprenol) is a promising alternative to gasoline due to its anti-knocking properties, 56 
comparable energy density, and comparable research octane number (Liu et al., 2014; 57 
Mack et al., 2014). Isoprenol is also a precursor for isoprene, a polymer building block 58 
used in the production of synthetic rubber (Ye et al., 2016). Production of isoprenol at 59 
various levels has been demonstrated in E. coli by extensive optimization of the 60 
mevalonate (MVA) pathway (George et al., 2015; Li et al., 2018; Zada et al., 2018; 61 
Zheng et al., 2013). The conventional MVA pathway includes condensation of three 62 
acetyl-CoA molecules and reduction to MVA along with two subsequent phosphorylation 63 
reactions by mevalonate kinase (MK) and 5-phosphomevalonate kinase (PMK). The 64 
product of phosphorylation, mevalonate diphosphate (MVAPP), is decarboxylated to 65 
isopentenyl diphosphate (IPP) by a diphosphomevalonate decarboxylase (PMD). Lastly, 66 
isoprenol is formed by hydrolysis of the pyrophosphate group from IPP, and overall these 67 
reactions consume 3 mol of ATP per mol of isoprenol. 68 
To overcome intrinsic limitations of the conventional MVA pathway, such as lower 69 
pathway efficiency and toxicity of an essential intermediate, IPP, an alternative IPP-70 
bypass MVA pathway (Figure 1A) has been developed by taking advantage of the 71 
promiscuous activity of PMD toward the non-native substrate mevalonate 72 
monophosphate (MVAP) (Kang et al., 2016). The advantages of this alternative pathway 73 
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over the conventional MVA pathway include the prevention of IPP toxicity by avoiding 74 
formation of IPP and increased robustness under lower aeration culture conditions, as this 75 
new pathway requires less ATP than the original MVA pathway (Kang et al., 2016). In a 76 
follow-up study, the PMD was engineered to have higher promiscuous activity towards 77 
mevalonate phosphate (MVAP), and isoprenol production was further improved to a titer 78 
of 1.2 g/L (Kang et al., 2017).  79 
While previous studies used rich media and small-scale batch fermentations to 80 
produce isoprenol, further improvements in yield and productivity using inexpensive 81 
media in larger volumes are required in order to derisk trials at commercial scale (Balan, 82 
2014; Hollinshead et al., 2014; Wehrs et al., 2019). In this study we optimize the IPP-83 
bypass mevalonate pathway for production of isoprenol in E. coli using several HMGR, 84 
HMGS and MK variants as well as engineered PMD mutants to provide optimal levels of 85 
the pathway intermediates. As a result of these engineering efforts, isoprenol production 86 
in minimal medium reached 3.7 g/L in batch cultures whereas a titer of 10.8 g/L was 87 
reached using fed-batch cultures with a solvent overlay in a 2-L bioreactor, which is the 88 
highest reported titer for this compound.   89 
 90 
2. Materials and Methods 91 
2.1. Plasmids and strains 92 
All plasmids and strains used in this study are listed in Table 1. Strains and plasmids 93 
along with their associated information (annotated GenBank-format sequence files) have 94 
been deposited in the public version of the JBEI Registry (https://public-registry.jbei.org) 95 
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and are physically available from the authors and/or Addgene (http://www.addgene.org) 96 
upon request. 97 
 98 
2.2. Batch production of isoprenol in E. coli 99 
Isoprenol production in EZ-Rich defined medium was performed as previously described 100 
(Kang et al., 2016). Briefly, to prepare seed cultures, each single colony was inoculated 101 
in LB (lysogeny broth) medium containing appropriate antibiotics and grown overnight. 102 
Seed cultures were diluted to an optical density (OD600nm) of 0.05 in EZ-Rich defined 103 
medium (Teknova, USA) supplemented with 10 g/L glucose (1 %, w/v) and two 104 
antibiotics, namely, 100 μg/mL ampicillin and 30 μg/mL chloramphenicol. Diluted cell 105 
cultures (5 mL) were first grown at 37°C with shaking at 200 rpm. When cell density 106 
reached an OD600nm value of 0.4-0.6, expression of proteins was induced with 0.5 mM 107 
IPTG, and the cultures were transferred to an incubator at 30°C with shaking at 200 rpm. 108 
Isoprenol production in defined minimal media was performed with M9-MOPS minimal 109 
medium (M9 medium (33.9 g/L Na2HPO4, 15 g/L KH2PO4, 5 g/L NH4Cl, 2.5 g/L NaCl) 110 
supplemented with 75 mM MOPS, 2 mM MgSO4, 1 mg/L thiamine, 10 nM FeSO4, 0.1 111 
mM CaCl2, and micronutrients including 3 × 10
-8 M (NH4)6Mo7O24, 4×10
-6 M boric acid, 112 
3×10-7 M CoCl2, 1×10
-7 M CuSO4, 8×10
-7 M MnCl2, and 1×10
-7 M ZnSO4) with glucose 113 
(10-30 g/L, depending on production conditions) as a sole carbon source.  114 
Strains used for production in minimal medium were first adapted in the medium by 115 
serially diluting cell cultures in fresh minimal medium. Briefly, each single colony was 116 
inoculated in LB overnight and diluted 50-fold (v/v) in M9-MOPS minimal medium. 117 
Cultures were grown for another 24 h and re-diluted 50-fold (v/v) in fresh M9-MOPS 118 
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medium. These steps were repeated four times, and the final cell cultures adapted to M9-119 
MOPS medium were stored as frozen glycerol stocks at -80°C. For batch production, a 120 
loopful of glycerol stock was inoculated in 2 mL M9-MOPS minimal medium with 1% 121 
glucose, and seed cultures were grown overnight at 37°C with shaking at 200 rpm and 122 
diluted 50-fold in 5 mL M9-MOPS medium with appropriate antibiotics and glucose at 123 
concentrations indicated. 124 
 125 
2.3. Isoprenol production in fed-batch fermenter 126 
Fed-batch fermentation was performed in a 2-L bioreactor (Sartorius BIOSTAT B plus) 127 
with control for dissolved oxygen (DO), pH, and temperature. A 5-mL culture was 128 
inoculated from a frozen glycerol stock, grown for 24 hours, and then used to inoculate a 129 
50-mL culture in a 250-mL flask; this culture was then used to inoculate the bioreactor to 130 
an OD600nm of 0.1. The medium for batch phase was M9 minimal medium supplemented 131 
with 2 mM MgSO4, 1 mg/L thiamine, 10 µM FeSO4, 0.1 mM CaCl2, additional NH4Cl (if 132 
needed), glucose (2% or 3% w/v), 10 g/L yeast extract (if needed), appropriate antibiotics 133 
and micronutrients including 3 × 10-8 M (NH4)6Mo7O24, 4×10
-6 M boric acid, 3×10-7 M 134 
CoCl2, 1.5×10
-7 M CuSO4, 8×10
-7 M MnCl2, and 1×10
-7 M ZnSO4. The pH of the culture 135 
was maintained at 7.0 by supplementation with a base solution (10 N KOH). 136 
Temperature, DO, and airflow were set to 30°C, 30%, and a rate of 1 VVM (volume of 137 
air per volume of liquid per minute), respectively, throughout the fermentation run. 138 
Protein expression was induced with 0.5 mM IPTG when the culture reached an OD600nm 139 
of 0.4-0.6. Glucose feeding started when the initial amount of glucose was depleted 140 
(indicated by a sharp increase in DO or HPLC analysis) with a feed solution containing 141 
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200 g/L glucose, 15 g/L MgSO4
.7H2O, 5 g/L yeast extract (if needed), micronutrients 142 
according to previous descriptions (Korz et al., 1995) and appropriate antibiotics; also, 143 
antifoam B was added to the bioreactor when required. Glucose feeding was carried out 144 
using a Watson-Marlow DU520 peristaltic pump; for constant feeding, the flow rate was 145 
selected to closely match the glucose consumption rate at the end of the batch phase. For 146 
exponential feeding, the feeding rate was changed every hour (for a total of 12 hours) and 147 
calculated according to the following equation (Korz et al., 1995):  148 
𝑚(𝑡) = (
𝜇
𝑌𝑋/𝑆
+𝑚)𝑉𝑡𝐹𝑋𝑡𝐹𝑒
𝜇(𝑡−𝑡𝐹), 149 
where m(t) is the mass flow of the substrate (g/h), µ is the specific growth rate (0.1 h-1), 150 
YX/S is the biomass/substrate yield coefficient (0.5 g/g), m is the specific maintained 151 
coefficient (0.025 g g-1 h-1), VtF is the cultivation volume at the time of feeding (tF) and 152 
XtF is the biomass concentration (g/L). After 12 hours of exponential feeding, the feeding 153 
rate was set constant and glucose was continuously measured in the medium, and the 154 
feeding rate was adjusted to prevent its accumulation at more than 2 g/L. For the two-155 
phase cultivation, 20% (v/v) oleyl alcohol was added to the fermenter at the time of 156 
induction. During the fed-batch phase, additional oleyl alcohol was added so its volume 157 
never decreased below 10% of the total volume. For OD600nm measurement and isoprenol 158 
quantification during the two-phase cultivation, the sample was first separated by 159 
centrifugation (8 min, 4000 x g) and the aqueous phase was used to quantify isoprenol as 160 
described above (except that up to 1:3 dilutions with ethyl acetate were used for isoprenol 161 
concentrations greater than 2 g/L) as well as OD600nm  and DCW (dry cell weight) 162 
measurements; in order to quantify isoprenol from the organic phase, 10 µL of the oleyl 163 
alcohol was added to 990 µL ethyl acetate containing 1-butanol as an internal standard 164 
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and the total isoprenol was calculated based on the actual culture volume at the time of 165 
the sampling.    166 
 167 
2.4. Isoprenol quantification by gas chromatography (GC) 168 
For isoprenol quantification, an aliquot of cell culture (250 μL) was combined with an 169 
equal volume of ethyl acetate (250 μL) containing 1-butanol (30 mg/L) as an internal 170 
standard and vigorously mixed for 15 min. Mixtures of cell cultures and ethyl acetate 171 
were centrifuged at 20,000 x g for 3 min, and 50 or 100 μL of the ethyl acetate layer was 172 
diluted 10-fold or 5-fold in ethyl acetate containing 1-butanol (30 mg/L). An aliquot (1 173 
μL) of each of the diluted samples was analyzed by gas chromatography – flame 174 
ionization detection (Thermo Focus GC) equipped with a DB-WAX column (15-m, 0.32-175 
mm inner diameter, 0.25-µm film thickness, Agilent, USA), the oven temperature 176 
program was as follows: started at 40°C, a ramp of 15°C/min to 100°C, a ramp of 177 
40°C/min to 230°C and held at 230°C for 3 min. 178 
 179 
2.5. Quantification of metabolites, sugars and fermentation acids. 180 
For analysis of metabolites from the IPP-bypass pathway, 0.5-1 mL of cell culture was 181 
centrifuged at 14,000 x g for 3 min at 4°C, the cell pellets were resuspended in 250 µL of 182 
methanol and stored at 20°C. Pellets were thawed on ice and combined with 250 μL 183 
water, the methanol-water mixtures were centrifuged at 15,000 rpm for 10 min at 4°C and 184 
the supernatant was filtered through a MilliporeTM Amicon Ultra 3kD MW cut-off filter 185 
at 14,000 x g for 45 min at 4°C. Filtered solutions were diluted with an equal volume of 186 
acetonitrile (final 50% (v/v) ACN) and analyzed via liquid chromatography-mass 187 
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spectrometry (LC-MS; Agilent Technologies 1200 Series HPLC system and Agilent 188 
Technologies 6210 time-of-flight mass spectrometer) on a ZIC-HILIC column (150-mm 189 
length, 4.6-mm internal diameter, and 5-µm particle size) (Baidoo et al., 2019). 190 
Concentrations of intracellular metabolites were calculated assuming cell volume of 1 191 
OD600nm /mL as 3.6 µL (Volkmer and Heinemann, 2011). 192 
For quantification of glucose and organic acids, 5 µL of filtered supernatant (0.45-µm 193 
centrifugal filter) was analyzed by isocratic elution with 4 mM sulfuric acid through an 194 
HPLC system equipped with an Aminex HPX-87H column (Bio-Rad, Richmond, CA, 195 
USA) and a refractive index detector (Agilent Technologies). The sample tray and 196 
column compartment were set to 4 and 50°C, respectively, and the flow rate was 197 
maintained at 0.6 mL/min. Data acquisition and analysis were performed via Chemstation 198 
software (Agilent Technologies). 199 
 200 
3. Results and Discussion 201 
3.1. Pathway optimization for the biosynthesis of MVAP  202 
For isoprenol production via the IPP-bypass mevalonate pathway, we initially expressed 203 
atoB (E. coli), HMGS_Sc_o (S. cerevisiae), HMGR_Sc_o (S. cerevisiae) and MK_Sc_co 204 
(S. cerevisiae, codon optimized) from a medium-copy plasmid and the PMD (S. 205 
cerevisiae) from a high-copy plasmid (Kang et al., 2016) (plasmid arrangements are 206 
shown in Figure 1B); isoprenol production reached 513 mg/L after 48 hours using EZ-207 
Rich medium supplemented with 1% glucose (strain AK01, Figure 2A). Using this strain 208 
as a baseline, we tested different expression levels of MK, HMGR, and HMGS in order 209 
to identify limiting steps for the biosynthesis of MVAP in the IPP-bypass pathway.  210 
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First, we tested whether increasing the expression of the MK would affect isoprenol 211 
production. We expressed MK (i.e., MK_Sc_co) from a high-copy plasmid (ColE1-212 
origin) with a Trc promoter instead of the medium-copy plasmid (p15A origin, Figure 213 
1C), which increased the isoprenol titer significantly, reaching 1.05 g/L (strain AK02, 214 
Figure 2A), suggesting that isoprenol production might be limited by MVAP levels. To 215 
test whether the changes in expression of the enzymes upstream of the MK such as 216 
HMGS and HMGR would also improve isoprenol production, we tested variants of these 217 
enzymes from different organisms (Table 1). The three HMGS variants tested were from 218 
S. cerevisiae (HMGS_Sc_o, native sequence; and HMGS_Sc_co, codon-optimized 219 
sequence) and from S. aureus (HMGS_Sa), and the five HMGR variants tested were from 220 
S. cerevisiae (HMGR_Sc_co, codon-optimized), S. aureus (HMGR_Sa), Bordetella petrii 221 
(HMGR_Bp), Delftia acidovorans (HMGR_Da), and Pseudomonas mevalonii 222 
(HMGR_Pm) (Ma et al., 2011). Both the HMGR_Sc_co and HMGR_Sa use NADPH as 223 
co-factor and have preference for the forward reaction (conversion of HMG-CoA to 224 
mevalonate), whereas the HMGR_Bp, HMGR_Da and HMGR_ Pm preferentially use 225 
NADH as cofactor (Ma et al., 2011). Different combinations of the HMGS and HMGR 226 
variants were tested while MK_Sc_co was expressed from the high copy plasmid. Figure 227 
2B shows that isoprenol production was improved when the HMGR_Sc_co and 228 
HMGS_Sc_co were used (1.34 g/L, strain AK07) and when HMGR_Sa was used in 229 
combination with either the HMGS_Sc_co (1.35g/L, strain AK08) or HMGS_Sa (1.26 230 
g/L, strain AK09). In general, lower isoprenol levels were observed when the NADH-231 
dependent HMGRs were used; since these HMGRs have relatively higher activity for the 232 
reverse reaction (conversion of mevalonate to HMG-CoA) (Ma et al., 2011), it is possible 233 
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that less carbon flux is being directed to the formation of mevalonate and downstream 234 
intermediates. Higher isoprenol titers were observed when the MK_Sc_co and the 235 
HMGRs with higher forward reaction activity were overexpressed, which suggests that 236 
production of isoprenol could be limited by the availability of mevalonate and 237 
mevalonate phosphate (MVAP). Several MK variants were also tested but titers were not 238 
improved (Figure 2C). We also tested if higher HMGR expression would positively 239 
affect carbon flux towards mevalonate as HMGR is known as a rate-limiting enzyme of 240 
the top pathway (acetyl-Co to mevalonate), but expression of an additional copy of the 241 
HMGR from a high-copy plasmid did not improve titers either (Figure 1D); in fact, a 242 
decrease in isoprenol production was observed compared to the control strain regardless 243 
of the HMGR variant used (Figure 2D). Further analysis of one of these HMGR-244 
overexpressing strains (strain AK19) showed that expression of this additional enzyme 245 
from the high-copy plasmid resulted in a lag phase after induction (Supplementary Figure 246 
1A), which indicates that growth of the strain was inhibited; the growth recovered after 247 
40 hours but this increase in cell biomass did not result in an increase of isoprenol 248 
production (Supplementary Figure 1B). Quantification of intermediate metabolites 249 
showed an increase in MVAP levels when the additional HMGR was expressed but no 250 
accumulation of other potentially toxic intermediates was observed (Supplementary 251 
Figure 1C). We also tested whether overexpression of the HMGR itself was toxic to the 252 
cells, but overexpression of only the HMGR_Sc_co from a pTrc promoter from a high-253 
copy number plasmid did not inhibit growth (data not shown).   254 
 255 
3.2. Pathway optimization with PMD mutants  256 
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Based on the results from the previous section, we hypothesized that the conversion of 257 
MVAP to IP might also be a bottleneck in the pathway. Therefore, in order to improve 258 
the conversion of MVAP to IP, we tested a PMD mutant (R74G) that was reported to 259 
have higher Ki than the wild-type PMD (MVAP is a non-competitive inhibitor of PMD)  260 
(Kang et al., 2017). Initially, both the wild-type PMD (strain AK07) and the R74G 261 
mutant (strain AK21) were expressed with enzyme variants described in the previous 262 
section containing the HMGS_Sc_co, HMGR_Sc_co, and MK_Sc_co. The maximum 263 
isoprenol titers of two strains were similar, but there was a significant improvement in 264 
rate of production with the R74G mutant (strain AK21) compared to the wild-type PMD 265 
(strain AK07), reaching a maximum titer of 1.6 g/L after 30 hours instead of 40 hours 266 
(Figure 3A). The strain AK21 also showed faster growth (Figure 3B) and faster glucose 267 
consumption (Supplementary Figure 2A). Acetate accumulation peaked at 6 hours after 268 
induction reaching 0.8 g/L in both strains, but it decreased to 0.5 g/L and 0.3 g/L in the 269 
AK07 and AK21 strains, respectively, at 30 hours after induction (Supplementary Figure 270 
2B). Slower assimilation of acetate for strain AK07 might explain the slower glucose 271 
consumption rate at the early stage after induction. In order to test how the use of the 272 
R74G PMD mutant affected the conversion of MVAP, we measured MVA, MVAP and 273 
IP over time (Figure 3B). Both the intracellular and extracellular concentrations of 274 
MVAP were significantly lower in the strain with the R74G mutant (strain AK21) 275 
compared to those of the strain with the wild-type PMD (strain AK07), whereas the IP 276 
levels were higher, suggesting that using the R74G mutant increases the conversion of 277 
MVAP to IP. The strain AK21 also showed lower mevalonate concentrations, suggesting 278 
that mevalonate was converted to MVAP more efficiently in strain AK21 than in strain 279 
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AK07, where mevalonate increased over time and reached a final concentration four 280 
times higher than in strain AK21 after 24 hours (Figure 3B). 281 
In addition to the R74G mutant, two other PMD mutants with higher kcat or higher Ki for 282 
MVAP were identified in our previous study, and these mutants could increase the 283 
conversion efficiency of MVAP to IP and improve isoprenol production (Kang et al., 284 
2017); one contains a single R74H mutation and the other contains three mutations, 285 
R74H, R147K and M212Q (abbreviated as HKQ). The PMD with these mutations were 286 
also tested with the HMGS_Sc_co-HMGR_Sc_co-MK_Sc_co system (strains AK22 and 287 
AK23, respectively) but lower isoprenol titers were observed (Figure 4A). We 288 
hypothesized that other HMGS, HMGR, and MK variants could provide different 289 
metabolite levels for the upstream intermediates, which could have synergistic effects on 290 
isoprenol production for the PMD mutants. Therefore, two additional strains containing 291 
the HMGS_Sa-HMGR_Sa-MK_mm or the HMGS_Sa-HMGR_Sa-MK_Sc_co (which 292 
showed high isoprenol titers in the previous section) were also tested with the PMD 293 
mutants (Figure 4A). Interestingly, very different isoprenol titers were observed for each 294 
PMD mutant depending on the HMGS-HMGS-MK system used; these differences were 295 
more significant with the R74H mutant, where the titer ranged from 784 mg/L for strain 296 
AK22 to 1.84 g/L for strain AK28 (Figure 4A). In general, higher titers were observed 297 
using the HMGS_Sa-HMGR_Sa-MK_Sc_co system, reaching a maximum titer of 1.84 298 
g/L with the R74H mutant (strain AK28) and 1.81 g/L with the HKQ mutant (strain 299 
AK29). 300 
 301 
3.3. Isoprenol production in minimal media 302 
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Because of its greater batch-to-batch consistency and lower cost, chemically defined 303 
minimal medium is usually employed for production in bench-scale fermentations; 304 
however, since all metabolites need to be synthesized de novo, growth in minimal 305 
medium can result in major shifts in cell resources and affect production (Singh et al., 306 
2017). Therefore, we tested our previously optimized strains for production on minimal 307 
medium supplemented with 1% glucose; isoprenol production was approximately half of 308 
that obtained with rich medium (Supplementary Figure S3). Increasing the glucose 309 
concentration to 2% generally resulted in higher titers, except for a few strains (e.g., 310 
AK28 and AK29), but the degree of improvement varied depending on the MK, HMGS, 311 
HMGR, and PMD variants used (Figure 4B). In general, strains with lower isoprenol 312 
production showed slower growth and higher acetate accumulation (data not shown). The 313 
highest isoprenol titer was achieved when the R74G PMD mutant was expressed with the 314 
HMGS_Sc_co-HMGR_Sc_co-MK_Sc_co system (strain AK21), reaching titers of 2.74 315 
g/L. Comparable titers were also observed with strains AK27, AK25 and AK26. 316 
Interestingly, more than a 10-fold difference in isoprenol titer was observed for the R74G 317 
mutant depending on the HMGS-HMGR-MK system used (ranging from 246 mg/L for 318 
strain AK24 to 2.74 g/L for strain AK21; Figure 4B). The initial glucose concentration 319 
affected not only the titer but also the yield; for example, for strain AK26, the yield from 320 
1% glucose was 0.095 g isoprenol per g glucose, whereas from 2% glucose the yield was 321 
0.14 g isoprenol per g glucose; the latter is close to 44% of the theoretical yield using the 322 
MVA pathway (Dugar and Stephanopoulos, 2011). In both cases, the stationary phase 323 
was reached after 20 hours (Figure 5A), therefore, it is possible that the higher yield with 324 
2% glucose was due to additional isoprenol produced during stationary phase when 325 
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production could occur without cell growth. The glucose consumption rates of AK26 in 326 
minimal medium supplemented with 2% glucose were slower (0.37 g glucose per hour) 327 
than those in the medium with 1% glucose (0.49 g glucose per hour; Figure 5B), but there 328 
was no significant difference in the isoprenol production rate or biomass production 329 
estimated by OD600nm while glucose was being consumed (Figure 5C). Although both the 330 
glucose consumption and isoprenol accumulation increased linearly until the glucose was 331 
fully consumed, it is interesting to note that no increase in growth (OD600nm) was 332 
observed after 22 hours regardless of the initial glucose concentration. This halted growth 333 
could be due to a limiting nutrient or the accumulation of growth inhibitors in the 334 
medium. After biomass production stopped at ~ 22 hr, isoprenol yield did not increase, 335 
suggesting that a portion of the remaining glucose was used for byproduct formation 336 
(e.g., acetate and ethanol): both fermentation byproducts showed a gradual increase 337 
during stationary phase, when ethanol accumulated to 1.2 g/L (Supplementary Figure 338 
S4). Three of the strains with the highest titers (AK21, AK26 and AK27) were further 339 
tested for production using minimal medium supplemented with 3% glucose (Figure 6). 340 
Interestingly, a significant improvement in titer was observed for strain AK26, reaching 341 
3.71 g/L of isoprenol after 63 hours (Figure 6A), but not for strains AK27 and AK21. A 342 
higher glucose consumption rate and less acetate accumulation were observed for strain 343 
AK26, which might explain the difference in titers (Figure 6B and 6C). The yield for 344 
strain AK26 using 3% glucose was the same as when 2% glucose was used (0.14 g 345 
isoprenol per g glucose), whereas ethanol accumulated to 1.9 g/L (Figure 6D) and acetate 346 
was not produced at significant levels (0.3 g/L, Figure 6B). Since the mevalonate 347 
pathway generates 6 mol of NADH per mol of isoprenol produced (Dugar and 348 
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Stephanopoulos, 2011), accumulation of ethanol suggests that glucose might be used for 349 
production of ethanol to regenerate NAD+ from excessive accumulation of NADH 350 
generated as a result of higher isoprenol production. When the glucose concentration was 351 
further increased to 4% and 5%, lower isoprenol titers, lower glucose consumption rate, 352 
and significant acetate accumulation were observed (data not shown), which is a 353 
signature feature of overflow metabolism (Basan et al., 2015; Szenk et al., 2017; Wolfe, 354 
2005).  355 
 356 
3.4. Fed-batch fermentation  357 
3.4.1. Media and feeding optimization 358 
To test if higher titers and yields of isoprenol could be achieved in a bioreactor by 359 
feeding additional glucose, the optimized strain presented in the previous section (strain 360 
AK26) was used for fed-bath fermentations in a 2-L bioreactor. M9 minimal medium 361 
with 2% glucose (see Material and Methods for full description of the medium 362 
components) was used during the batch phase, and glucose was continuously added at a 363 
constant rate when the initial glucose was depleted, indicated by a sharp increase in DO 364 
or by HPLC analysis of the glucose level. This initial fermentation is referred to as Ferm 365 
1 and subsequent fermentations are numbered accordingly (for a description of all 366 
cultivation conditions and a summary of titers, yields, and productivities, see 367 
Supplementary Table S1). Figure 7A shows that production of isoprenol for Ferm 1 368 
continuously increased during the fermentation, reaching a titer of 3.55 g/L and a yield of 369 
0.048 g/g glucose at 150 hours, which is lower than what we observed under shake flask-370 
conditions (yield of 0.14 g/g glucose). The growth profile of Ferm 1 (Figure 7B) showed 371 
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that the OD600nm reached 6.2 at 22 hours and that the glucose in the batch medium was 372 
depleted after 48 hours of cultivation (Supplementary Figure S5). This result suggests 373 
that growth was halted even before all glucose was consumed. Therefore, we hypothesize 374 
that nutrients other than glucose might be limiting growth during the batch phase. When 375 
we increased the concentration of the nitrogen source (NH4Cl) in the batch medium, from 376 
a C/N ratio of 18 in Ferm 1 to a ratio of 10 (Ferm 2), a maximum OD600nm of 7.5 was 377 
reached at 22 hours (see Ferm 2 in Figure 7B). Also, there was a significant reduction in 378 
the time needed for the complete consumption of the initial glucose in the batch culture 379 
from 55 hours to 30 hours (see Supplementary Figure S5), reflecting a higher glucose 380 
consumption rate for Ferm 2 compared to that of Ferm 1. Despite the higher biomass 381 
accumulation during the batch phase, the maximum isoprenol titer for Ferm 2 was 3.44 382 
g/L at 119 hours, which is similar to that of Ferm 1 (Figure 7A).  383 
Instead of feeding glucose at a constant rate, more efficient feeding strategies have been 384 
developed in order to prevent overfeeding or underfeeding of the substrate; in particular, 385 
feeding the limiting substrate at an exponentially increasing rate results in constant 386 
specific growth rates (Korz et al., 1995). Therefore, we changed the feeding strategy from 387 
constant feeding to exponential feeding (see Materials and Methods for details). As 388 
shown in Figure 7B the exponential feeding strategy (Ferm 3) resulted in a continuous 389 
increase in OD600nm during the first 50 hours of the fermentation (c.f. batch phase ended 390 
ca. 30 hours), a maximum OD600nm of 11.1, and a significant increase in isoprenol titer, 391 
reaching a maximum titer of 4.86 g/L.  392 
It has been shown that E. coli growth on minimal medium containing ammonium salts as 393 
a sole nitrogen source can be significantly improved by supplementing the medium with 394 
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an organic nitrogen source such as yeast extract, as it provides amino acids that can be 395 
directly used for enzyme synthesis (Hugo and Lund, 1968). Therefore, we supplemented 396 
the cultivation medium with yeast extract (10 g/L in the batch phase and 5 g/L during the 397 
fed-bath phase) to test its effect on growth and production of isoprenol. As can be seen in 398 
Figure 7B (Ferm 4), supplementing the medium with yeast extract resulted in higher OD 399 
values compared to previous fermentations, reaching a maximum OD600nm of 16.7. 400 
Moreover, the isoprenol titer also improved, reaching a maximum of 5.42 g/L after 94 401 
hours. Since exponential feeding and the addition of yeast extract (which constituted less 402 
than 10% of the total carbon added) resulted in significant improvements in OD600nm and 403 
titer, these conditions were used for further fermentations. 404 
 405 
3.4.2. Reduction of acetate formation  406 
During the optimization of the medium and feeding strategy, it was observed that the 407 
OD600nm of the culture decreased after 46 hours (see Ferm 4 in Figure 7B), and a 408 
significant amount of acetate (1.5 g/L) was observed at 54 hours; acetate concentration 409 
continued to increase to more than 6.6 g/L by the end of the fermentation (see Ferm 4 in 410 
Figure 8A). Acetate accumulation not only represents a loss of carbon but it can also be 411 
detrimental to cell growth at concentrations as low as 1 g/L, affecting the stability of 412 
intracellular proteins and acting as proton conductor that can reduce proton motive force 413 
(Eiteman and Altman, 2006; De Mey et al., 2007). Two main pathways are responsible 414 
for acetate production in E. coli, the pyruvate oxidase and the acetate kinase - 415 
phosphotransacetylase pathway, which are encoded by the poxB and ackA/pta genes, 416 
respectively (see Figure 1A). To minimize acetate production during the fermentation, a 417 
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strain in which these acetate-pathway genes were deleted (strain AK30) was used for 418 
isoprenol production in the fermenter. No acetate was detected during the fermentation 419 
when this mutant strain was used (Ferm 5, Figure 8A); moreover, there was no significant 420 
decrease in OD600nm during the cultivation as was previously observed for the wild-type 421 
strain (Ferm 4, Figure 7B).  422 
The glucose consumption rate for the mutant strain was similar to that of the wild-type 423 
strain (Figure 8D) but the isoprenol titer increased 14%, reaching 6.15 g/L after 95 hours 424 
(Figure 8C). This result suggests that removal of acetate pathway prevented the loss of 425 
carbon to acetate, improving the conversion of glucose in Ferm 5. When the glucose 426 
concentration in the batch phase was increased from 2% to 3%, the isoprenol titer was 427 
further improved, reaching a maximum of 6.84 g/L at 79 hours (yield of 0.084 g/g); no 428 
significant accumulation of acetate was detected (see Ferm 6 in Figure 8) as was the case 429 
for Ferm 5. The maximum OD600nm was greater with 3% glucose in which additional 430 
NH4Cl was added to maintain a C/N = 10, reaching a value of 25 at 33 hours. This result 431 
suggests that the conversion of glucose into isoprenol was further improved by increasing 432 
biomass available during fed-batch phase. Based on these results, we used the strain with 433 
the acetate-pathway genes deleted for further optimization of the isoprenol production 434 
with 3% initial glucose.   435 
3.4.3. Use of a solvent overlay: two-phase cultivation 436 
As shown in Figure 8B, there was no significant increase in OD600nm after 35 hours 437 
regardless of acetate accumulation or higher glucose in the batch phase (Ferm 4-6). In 438 
fact, most of the acetate accumulation in Ferm 4 was observed after 50 hours, suggesting 439 
that acetate toxicity may not be the reason for the halted growth after 35 hours. Besides 440 
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acetate accumulation, there was an observed relationship between the time at which the 441 
culture stopped growing and the time at which higher isoprenol titers were reached. As 442 
shown in Figures 7 and 8, no significant increase in OD600nm values was observed after 443 
isoprenol titers reached more than 3 g/L, suggesting that high isoprenol concentration 444 
might be a reason for the halted growth  It is known that exposure to short-chain alcohols 445 
can result in compromised cell membranes, causing uncontrolled transport of solutes, 446 
leakage of important cofactors, and inactivation of membrane and cytosolic enzymes, 447 
resulting in a decline in growth rate and cell viability (Huffer et al., 2011; Ingram, 1986). 448 
In the case of E. coli, it has been reported that isoprenol can be toxic at concentrations as 449 
low as 2.4 g/L (Foo et al., 2014). Two-phase cultivations, in which an organic solvent is 450 
used to continuously extract a product in situ, can be used as a strategy to reduce the toxic 451 
effects of the product and to increase its yield (Malinowski, 2001). In particular, oleyl 452 
alcohol has been shown to be an effective solvent for the extraction of short-chain 453 
alcohols in two-phase cultivations (Connor et al., 2010; Roffler et al., 1987).  454 
Therefore, oleyl alcohol (20% v/v) was added to the bioreactor at the time of induction 455 
and the cultivation was carried out as described in the previous section, except that 456 
isoprenol was measured both in the aqueous and the organic phases. When the two-phase 457 
cultivation with oleyl alcohol (Ferm 7) was used, significantly higher OD values were 458 
achieved compared to those of the one-phase cultivation (Ferm 6; Figure 9A); moreover, 459 
the OD600nm from two-phase cultivation (Ferm 7) increased throughout cultivation and 460 
reached a maximum value of 44.6 at 95 hours, which is a substantial improvement in 461 
growth compared to Ferm 6. Accumulation of greater biomass during the two-phase 462 
cultivation (Ferm 7) was confirmed by DCW measurements (see Supplementary Figure 463 
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S6A). Isoprenol production was also significantly higher when the two-phase cultivation 464 
strategy was used (Figure 9B), reaching a maximum titer of 10.8 g/L at 95 hr with a yield 465 
of 0.105 g/g glucose and a maximum productivity of 0.157 g L-1 hr-1. Further analysis 466 
showed that the amount of isoprenol coming from the aqueous phase accounts for ca. 467 
62% (6.7 g/L) of the total isoprenol produced and the amount of isoprenol coming from 468 
the oleyl alcohol phase accounts for ca. 38% (4.1 g/L) of the total isoprenol produced 469 
(Supplementary Figure S6C). It is noteworthy that the maximum aqueous-phase 470 
concentration of isoprenol for the two-phase cultivation was very similar to the maximum 471 
concentration reached in the fermentation without an overlay (see Figure 9B and 472 
Supplementary Figure S6D). This result shows that a continuous product extraction using 473 
an overlay can be an effective strategy for producing isoprenol at high titers and reducing 474 
its detrimental effect on growth by maintaining a low concentration of the toxic product 475 
in the producing culture.  476 
Since the use of two-phase fermentations at larger scales could be challenging in terms of 477 
the cost and the downstream processing, production of isoprenol at high titers and at 478 
larger scales might require the development of strategies to alleviate the toxicity of 479 
isoprenol without the use of organic solvents. Improving E. coli’s tolerance to isoprenol 480 
by expressing efflux pumps or transporters (Foo et al., 2014) or by directed evolution is a 481 
promising strategy that could allow production at high titers without the need for two-482 
phase fermentation, but further host engineering would be required for this goal. 483 
 484 
4. Conclusion 485 
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The IPP-bypass pathway was optimized for production of isoprenol in E. coli by 486 
improving the biosynthesis of MVAP and its conversion to IP, a direct precursor of 487 
isoprenol. A series of metabolic engineering efforts improved the isoprenol production 488 
substantially, reaching 3.7 g/L (0.14 g isoprenol per g glucose) in batch fermentations 489 
using minimal medium. The use of fed-batch fermentation allowed production of 490 
isoprenol at 10.8 g/L, which is the highest reported titer for this compound. In addition to 491 
medium optimization and the elimination of acetate accumulation, production at high 492 
titers required the use of a two-phase cultivation process whereby isoprenol was partially 493 
removed from the aqueous phase into an organic overlay. The removal of isoprenol from 494 
the aqueous phase contributed to relieving its toxicity, resulting in considerably higher 495 
biomass levels in the cultivation with an organic overlay.     496 
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Table 1. Strains and plasmids used in this work 611 
Strain Description Reference 
DH1 Wild type DH1  
AK01 DH1 with plasmids JBEI-9310 + JBEI-9314 (Kang et al., 
2016) 
AK02 DH1 with plasmids JBEI-2703 + JBEI-12064 This work 
AK03 DH1 with plasmids JBEI-17856 and JBEI-12064 This work 
AK04 DH1 with plasmids JBEI-3093 and JBEI-12064 This work 
AK05 DH1 with plasmids JBEI-3092 and JBEI-12064 This work 
AK06 DH1 with plasmids JBEI-17835 and JBEI-12064 This work 
AK07 DH1 with plasmids JBEI-3100 and JBEI-12064 This work 
AK08 DH1 with plasmids JBEI-17837 and JBEI-12064 This work 
AK09 DH1 with plasmids JBEI-17081 and JBEI-12064 This work 
AK10 DH1 with plasmids JBEI-3100 and JBEI-17847 This work 
AK11 DH1 with plasmids JBEI-3100 and JBEI-17864 This work 
AK12 DH1 with plasmids JBEI-3100 and JBEI-17865 This work 
AK13 DH1 with plasmids JBEI-17081 and JBEI-17847 This work 
AK14 DH1 with plasmids JBEI-3100 and JBEI-17866 This work 
AK15 DH1 with plasmids JBEI-3100 and JBEI-17862 This work 
AK16 DH1 with plasmids JBEI-3100 and JBEI-17861 This work 
AK18 DH1 with plasmids JBEI-3100 and JBEI-17853 This work 
AK19 DH1 with plasmids JBEI-3100 and JBEI-17852 This work 
AK20 DH1 with plasmids JBEI-3100 and JBEI-17857 This work 
AK21 DH1 with plasmids JBEI-3100 and JBEI-17839 This work 
AK22 DH1 with plasmids JBEI-3100 and JBEI-17841 This work 
AK23 DH1 with plasmids JBEI-3100 and JBEI-17840 This work 
AK24 DH1 with plasmids JBEI-17081 and JBEI-17846 This work 
AK25 DH1 with plasmids JBEI-17081 and JBEI-17845 This work 
AK26 DH1 with plasmids JBEI-17081 and JBEI-17844 This work 
AK27 DH1 with plasmids JBEI-17081 and JBEI-17839 This work 
AK28 DH1 with plasmids JBEI-17081 and JBEI-17841 This work 
AK29 DH1 with plasmids JBEI-17081 and JBEI-17840 This work 
DH1-KO DH1 pta-ackA poxB (Tian et al., 
2019) 
AK30 DH1-KO with plasmids JBEI-17081 and JBEI-17844 This work 
 612 
Plasmid Description Reference 
JBEI-9310 pA5c- AtoB-HMGS_Sc_o-HMGR_Sc_o-
MK_co  
(Kang et al., 2016) 
JBEI-9314 pTrc99a-PMDsc (Kang et al., 2016) 
JBEI-2703 pA5c-AtoB-HMGS_Sc_o-HMGR_Sc_o  (Ma et al., 2011) 
JBEI-17856 pA5c-AtoB-HMGS_Sc_o-HMGR_Pm (Ma et al., 2011) 
JBEI-3093 pA5c-AtoB-HMGS_Sc_o-HMGR_Da (Ma et al., 2011) 
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JBEI-3092 pA5c-AtoB-HMGS_Sc_o-HMGR_Bp (Ma et al., 2011) 
JBEI-17835 pA5c-AtoB-HMGS_Sc_co-HMGR_Bp This work 
JBEI-3100 pA5c-AtoB-HMGS_Sc_co-HMGR_Sc_co (Ma et al., 2011) 
JBEI-17837 pA5c-AtoB-HMGS_Sc_co-HMGR_Sa This work 
JBEI-17081 pA5c-AtoB-HMGS_Sa-HMGR_Sa (Ma et al., 2011) 
   
JBEI-12064 pTrc99a-PMDsc-MK_co (Kang et al., 2016) 
JBEI-17847 pTrc99a-PMDsc-MK_Mm This work 
JBEI-17864 pTrc99a-PMDsc-MK_Sa This work 
JBEI-17865 pTrc99a-PMDsc-MK_Sn This work 
   
JBEI-17866 pTrc99a-PMDsc-MK_co-HMGR_Bp This work 
JBEI-17862 pTrc99a-PMDsc-MK_co-HMGR_Da This work 
JBEI-17861 pTrc99a-PMDsc-MK_co-HMGR_Pm This work 
JBEI-17853 pTrc99a-PMDsc-MK_co-HMGR_Sc_o This work 
JBEI-17852 pTrc99a-PMDsc-MK_co-HMGR_Sc_co This work 
JBEI-17857 pTrc99a-PMDsc-MK_co-HMGR_Sa This work 
   
JBEI-17844 pTrc99a-PMDsc_HKQ-MKmm This work 
JBEI-17846 pTrc99a-PMDsc_R74G-MKmm This work 
JBEI-17845 pTrc99a-PMDsc_R74H-MKmm This work 
JBEI-17840 pTrc99a-PMDsc_HKQ-MK_Sc_co This work 
JBEI-17839 pTrc99a-PMDsc_R74G-MK_Sc_co This work 
JBEI-17841 pTrc99a-PMDsc_R74H-MK_Sc_co This work 
 613 
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FIGURE LEGENDS 615 
Figure 1. Isoprenol production pathway and plasmids for heterologous pathway 616 
expression (A) Pathway reactions and relevant enzymes for isoprenol production. 617 
Heterologous enzymes targeted for engineering are highlighted in filled dark arrows. (B-618 
D) configuration of two plasmids used in this study. (B) Configuration used only in strain 619 
AK01. (C) Format used for MK variants, HMGS-HMGR variants, and PMD variants. (D) 620 
Format used for the expression of additional HMGR. 621 
 622 
Figure 2. Optimization of intermediates for MVAP biosynthesis.  (A) Isoprenol titer with 623 
MK expressed from a medium-copy plasmid (p15A origin) or high-copy plasmid (ColE1 624 
origin); (B) Production with HMGS and HMGR from different sources; (C) Isoprenol 625 
production with MK from various sources; (D) Expression of an additional copy of 626 
HMGR. Error bars represent one standard deviation from three biological replicates. 627 
Cultures were grown in test tubes with EZ-Rich medium at 30°C, induction at OD600nm = 628 
0.4-0.6 with 0.5 mM IPTG, and isoprenol production was measured at 48 hr. Sc_o: S. 629 
cerevisiae wild type, Sc_co: S. cerevisiae codon optimized, Sa: S. aureus, Bp: Bordetella 630 
petrii, Da: Delftia acidovorans, Pm: Pseudomonas mevalonii, Mm: M. masei, Sn: 631 
Streptococcus pneumoniae, MK: mevalonate kinase, HMGS=HMG-CoA synthase, 632 
HMGR= HMG-CoA reductase 633 
 634 
Figure 3. Comparison of strains containing wild-type PMD (strain AK07) and the R74G 635 
PMD mutant (strain AK21). (A) Isoprenol production and growth; (B) Mevalonate 636 
(MVA) and mevalonate phosphate (MVAP) levels. Error bars represent one standard 637 
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deviation from three biological replicates of EZ-Rich medium (50 mL in 250-mL flasks) 638 
supplemented with 1% glucose at 30°C. 639 
 640 
Figure 4. Effect of PMD mutants and HMGS-HMGR-MK systems on isoprenol 641 
production. (A) Production in EZ-Rich medium; (B) Production in minimal medium. 642 
PDM with the single mutations R74G or R74H, or with triple mutation R74H, R147K, 643 
and M212Q (HKQ) were tested with different HMGS, HMGR, and MK. Figure shows 644 
the average of three biological replicates of cultures grown at 30°C. EZ Rich medium 645 
was supplemented with 1% glucose and isoprenol production was measured at 48 hr.  646 
Minimal medium was supplemented with 2% glucose and isoprenol production was 647 
measured at 63 hr. Sc_co = S. cerevisiae, codon-optimized; Sa = S. aureus; Mm = M. 648 
mazei. 649 
 650 
Figure 5. Data from strain AK26 grown on minimal medium supplemented with 1% and 651 
2% glucose. (A) Growth; (B) glucose concentration in the medium; (C) isoprenol 652 
production. Cultures were grown in flasks at 30°C and error bars represent one standard 653 
deviation from three biological replicates. 654 
 655 
Figure 6. Comparison of the optimized strains (AK21, AK26, and AK27) in minimal 656 
medium supplemented with 3% glucose at different time points. (A) Isoprenol 657 
production; (B) Acetate accumulation; (C) Glucose consumption; (D) Ethanol 658 
accumulation. Cultures were grown in test tubes at 30°C and induced at OD600nm 0.4-0.6 659 
with 0.5 mM IPTG. 660 
33 
 
 661 
Figure 7. Media and feeding optimization. (A) Isoprenol titer; (B) optical density 662 
(OD600nm). Fermentations were run at 30°C with 2% glucose in the batch medium using 663 
strain AK26. Ferm 1: batch medium with C/N=18 and constant feeding, feed started at 54 664 
hours; Ferm 2: batch medium with C/N=10 and constant feeding, feed started at 31 hours; 665 
Ferm 3: batch medium with C/N=10 and exponential feeding, feed started at 31 hours; 666 
Ferm 4: batch medium with C/N=10, 10 g/L yeast extract and exponential feeding, feed 667 
started at 23 hours. 668 
 669 
Figure 8. Elimination of acetate production. (A) acetate accumulation; (B) optical 670 
density (OD600nm); (C) isoprenol titer; (D) glucose consumption. Fermentations were run 671 
at 30°C with 10 g/L yeast extract in the batch medium and exponential feeding. Ferm 4: 672 
DH1 strain, batch medium with 2% glucose (strain AK26), feed started at 23 hours; Ferm 673 
5: DH1 poxB ackA pta strain, batch medium with 2% glucose (strain AK30), feed 674 
started at 23 hours; Ferm 6: DH1 poxB ackA pta strain, batch medium with 3% 675 
glucose (strain AK30), feed started at 25 hours.  676 
 677 
Figure 9. Two-phase fermentation. (A) Optical density (OD600nm); (B) isoprenol titer. 678 
Fermentations using the DH1 poxB ackA pta strain (AK30), run at 30°C with 3% 679 
glucose and 10 g/L yeast extract in the batch medium, exponential feeding. Ferm 6: 680 
without overlay; Ferm 7: with 20% (v/v) oleyl alcohol overlay. For both Ferm 6 and 7, 681 
feed started at 25 hours. 682 
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Supplementary Figure S1. Analysis of additional HMGR expression on (A) growth by OD600nm, (B) isoprenol 
production, and (C) intracellular and extracellular intermediate concentrations 
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Supplementary Figure S2. Comparison of strains containing the wild type PMD (strain AK07) and the PMD with the 
R74G mutation (strain AK21). (A) Glucose remaining in the medium, (B) Acetate  
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Supplementary Figure S3. Production in minimal medium supplemented with 1% 
glucose. Production was measured at 24 hours.  
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Supplementary Figure S4. Comparison of strain AK26 grown on minimal medium supplemented with 1% and 
2% glucose. (A) Acetate accumulation; (B) Ethanol accumulation  
Supplementary Figure S5. Effect of NH4Cl concentration on glucose consumption  
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Supplementary Figure S6. Two phase fermentation. (A) comparison of dry cell weight (DCW); (B) 
glucose consumption; (C) distribution of isoprenol in the aqueous phase and oleyl alcohol phase at 
different time-points (Ferm 7); (D) isoprenol production in one-phase fermentation (Ferm 6). Ferm 6 
corresponds to one-phase fermentation and Ferm 7 corresponds to two-phase fermentation 
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Name	 Strain	 Batch	medium	 Feeding	 Max	Titer	
(g/L)	
Yield	(g/
g)	
ProducCvity	
(g	L-1	h-1)	
Ferm	1	 DH1	 2%	glucose,	C/N=18	 constant	 3.55	 0.048	 0.031	
Ferm	2	 DH1	 2%	glucose,	C/N=10	 constant	 3.44	 0.054	 0.040	
Ferm	3	 DH1	 2%	glucose,	C/N=10	 exponenLal	 4.86	 0.065	 0.062	
Ferm	4	 DH1	 2%	glucose,	yeast	extract	 exponenLal	 5.42	 0.069	 0.079	
Ferm	5	 DH1	ΔpoxB	ΔackA-pta	 2%	glucose,	yeast	extract	 exponenLal	 6.15	 0.082	 0.098	
Ferm	6	 DH1	ΔpoxB	ΔackA-pta	 3%	glucose,	yeast	extract	 exponenLal	 6.84	 0.073	 0.121	
Ferm	7	 DH1	ΔpoxB	ΔackA-pta	 3%	glucose,	yeast	extract,	oleyl	alcohol	overlay	 exponenLal	 10.88	 0.105	 0.157	
Supplementary Table S1: Titers, yields and maximum productivities for the different strains and 
fermentation conditions used in this study. Yield calculations correspond to the time at which the maximum 
titer was  reached (grams of isopentenol /grams of glucose consumed). Productivity corresponds to the 
maximum productivity reached during the fermentation 
   
